Bozzetti F, Saccozzi R, De Lena M, Salvadori B
J Surg Oncol. 1981;18(4):355-61. doi: 10.1002/jso.2930180405.
One hundred and fourteen cases of inflammatory breast cancer were reviewed. Actuarial survival curves, independent of the stage and type of treatment, showed a median survival of less than 15 months. As regards the three different subgroups of 80, 14, and 20 women, N0-1-2M0, N3M1 respectively, the acutuarial survival curves showed figures of median survival that decreased from 14 to 4 months, according to the extent of the disease. Survival rates for the subgroups of patients treated by radical mastectomy, radical mastectomy followed by radiotherapy, and radiotherapy alone were not significantly different. Neither the more sophisticated therapeutic approaches intended to modify the hormonal medium of the patients, nor the combined chemotherapy plus radiotherapy, proved to be successful. Inflmmatory breast cancer should be considered a systemic disease; consequently, in spite of discouraging results, only a systemic therapeutic approach, consisting of aggressive combination chemotherapy and perhaps immunostimulation, seems worthwhile.
回顾了114例炎性乳腺癌病例。不考虑分期和治疗类型的精算生存曲线显示,中位生存期少于15个月。对于分别为80名、14名和20名女性的三个不同亚组,即N0 - 1 - 2M0、N3M1,精算生存曲线显示,根据疾病程度,中位生存数字从14个月降至4个月。接受根治性乳房切除术、根治性乳房切除术后放疗以及单纯放疗的患者亚组的生存率没有显著差异。旨在改变患者激素环境的更复杂治疗方法以及化疗加放疗联合治疗均未取得成功。炎性乳腺癌应被视为一种全身性疾病;因此,尽管结果令人沮丧,但只有由积极联合化疗或许还有免疫刺激组成的全身性治疗方法似乎值得一试。